Rangsubbs Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 20-05-2024
- Paid Up Capital ₹ 1.39 Cr
as on 20-05-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2018
About Rangsubbs Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.39 Cr, as per Ministry of Corporate Affairs (MCA) records.
Srinivas Boyalapalli and Devarakonda Sankar serve as directors at the Company.
- CIN/LLPIN
U24302TG2017PTC119103
- Company No.
119103
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Aug 2017
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Rangsubbs Pharmaceuticals (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinivas Boyalapalli  | Managing Director | 24-Aug-2017 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Devarakonda Sankar | Director | 16-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Rangsubbs Pharmaceuticals (India).
Rangsubbs Pharmaceuticals (India) Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rangsubbs Pharmaceuticals (India)?
In 2018, Rangsubbs Pharmaceuticals (India) had a promoter holding of 55.10% and a public holding of 44.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indira Ravi Healthcare India Private LimitedActive 3 years 7 monthsSrinivas Boyalapalli and Devarakonda Sankar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rangsubbs Pharmaceuticals (India)?
Rangsubbs Pharmaceuticals (India) has a workforce of 1 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rangsubbs Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rangsubbs Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
